Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today May 3, 2022
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government Apr 27, 2022
Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities Apr 19, 2022
REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments Apr 18, 2022
Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility Apr 18, 2022
Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments Apr 14, 2022
Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company Mar 23, 2022
